AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-4137808_ITM" title="Facts and information about Soriatane's new labeling focuses on pregnancy. (Psoriasis Drug).">Soriatane's new labeling focuses on pregnancy. (Psoriasis Drug).</a>
Close
Set up an RSS feed that alerts you when new articles from OB GYN News are available.
Frequently asked questions about RSS feeds
Soriatane's new labeling focuses on pregnancy. (Psoriasis Drug).
MAUI, HAWAII -- Newly updated labeling for the psoriasis drug Soriatane places more emphasis than ever on pregnancy-related issues.
The prominent black box warning at the front of the package insert contains a new requirement that patients of childbearing potential must have two negative urine or serum pregnancy tests with sensitivity of at least 25 mIU/mL before the drug is prescribed, even though Soriatane (acitretin), unlike the antiacne drug Accutane (isotretinoin), isn't typically used in women with childbearing potential, Dr. Ronald W. Gottschalk said at the annual Hawaii dermatology seminar sponsored by the Skin Disease Education Foundation.
The black box also contains a new warning that St. John's wort, ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Guidelines for Practice: Caring for Women of Childbearing Potential Taking...
- Magazine article from: Dermatology Nursing Rudy, Sherrill Jantzi Pinto, Carissa Townsend-Akpan, Carleen February 1, 2001 700+ words
...considered whenever a woman of childbearing potential receives a drug. Although many...professionals who treat women of childbearing potential. A multiple choice examination...to be obtained from a woman of childbearing potential being considered for treatment...
- Biologic agents for psoriasis.(Drug Update)
- Magazine article from: Family Practice News Zoler, Mitchel L. Kirn, Timothy F. April 1, 2005 700+ words
...agents, but this assessment is based only on animal studies. If these drugs are used to treat women with childbearing potential, there is a risk of inadvertent exposure to a fetus during early pregnancy because biologics have a long elimination...
- National Psoriasis Foundation speaks out in support of new psoriasis...
- Magazine article from: Dermatology Nursing Gorgos, Diana October 1, 2004 700+ words
...the Psoriasis Foundation supports use of a risk management program for oral tazarotene focused on women of childbearing potential, to minimize to the greatest extent feasible the likelihood that a woman will become pregnant while taking...
- Agouron puts its computer-made drug to ultimate test - in patients. (Agouron...
- Magazine article from: San Diego Business Journal Fikes, Bradley J. January 20, 1992 700+ words
...clinical trials of its anti-psoriasis drug, named AG-85, and preliminary...bacterial infections, the anti-psoriasis drug is the furthest along in development...Agouron estimates the anti-psoriasis drug will hit the market in 1995...
- SAMI LABS TO LAUNCH PSORIASIS DRUG (is conducting clinical trials of the...
- Magazine article from: India Business Insight March 22, 2007 700+ words
...drugs of plant origin to cure psoriasis, cancer and lifestyle diseases. The company is conducting clinical trials of the psoriasis drug in 300 human volunteers in major Indian hospitals. The company plans to launch the drug in the domestic market in the next...
- Lupin got DCGI approval for its anti-psoriasis drug.
- News wire article from: PTI - The Press Trust of India Ltd. November 28, 2005 700+ words
Lupin got DCGI approval for its anti-psoriasis drug New Delhi, Nov 28 (PTI) Lupin Ltd today said it has...conducting phase II clinical trials for its new anti-psoriasis drug from the Drug Controller General of India. The new drug...
- FDA Advises Public of Serious Adverse Event with Psoriasis Drug Raptiva.
- Press release article from: M2 Presswire February 20, 2009 700+ words
...Administration: FDA Advises Public of Serious Adverse Event with Psoriasis Drug Raptiva(C)1994-2009 M2 COMMUNICATIONS LTD RDATE...PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab). Three of those patients have died...
- AGOURON PHARMACEUTICALS CLEARED TO COMMENCE CLINICAL TESTING OF PSORIASIS DRUG
- Press release article from: PR Newswire November 4, 1991 700+ words
...PHARMACEUTICALS CLEARED TO COMMENCE CLINICAL TESTING OF PSORIASIS DRUG SAN DIEGO, Nov. 4 /PRNewswire/ -- Agouron Pharmaceuticals...psoriasis. The clinical evaluation of Agouron's novel psoriasis drug is expected to be the first clinical study of any drug engineered...
- Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and...
- Press release article from: PR Newswire December 2, 2008 700+ words
...Abbott/Eisai's Humira, will drive the moderate to severe psoriasis drug market to more than double to nearly $5 billion over the...Pharmacor report entitled Psoriasis finds that the overall psoriasis drug market will grow from $2.3 billion in 2007 to $5 billion...
- Psoriasis drug market to reach $3.9 billion in 2011.
- Newspaper article from: Drug Week December 13, 2002 700+ words
2002 DEC 13 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., forecasts that the psoriasis drug market will reach $3.9 billion in 2011. A major factor in growth of the market, especially in the first half of the 2001...
Source: HighBeam Research, Soriatane's new labeling focuses on pregnancy. (Psoriasis Drug).